Mereo Biopharma Group Plc

Mereo Biopharma (MPH)

Company name:Mereo Biopharma Group Plc
EPIC:MPHTrading Currency:GBX
Market Sector:AMSRISIN:GB00BZ4G2K23
Market Segment:ASX1Share Type:DE
WWW Address: GBP0.003 (REG S)
 Price Price Change [%] Bid Offer Open High Low Volume
 26.50 0.0 [0.00] 26.00 27.00 - - - -
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 72.52 273.65 0.19 -39.00 - - - 32.50 - 26.00

Mereo Biopharma Key Figures

(at previous day's close)
Market Cap.72.52m
Shares In Issue273.65m
Prev. Close26.50
PE Ratio- 
Dividend Yield-%
EPS - basic-39.00p
Dividend PS-p
Dividend Cover- 
Cash Flow PS-16.78p
Return On Equity (ROE)-86.56%
Operating Margin-%
PEG Factor- 
EPS Growth Rate13.33%
Dividends PS Growth Rate-%
Net Debt29.85m
Gross Gearing53.43%
Quick Assets30.44m
Net Working Capital0.56m
Intangibles / Fixed Assets79.37%
Turnover PS-p
Pre-Tax Profit PS-15.03p
Retained Profit PS-12.73p
Cash PS5.97p
Net Cash PS-4.94p
Net Tangible Asset Value PS *-1.53p
Net Asset Value PS14.71p
Spread1.00 (3.70%) 

Mereo Biopharma Balance Sheet


Share Price Performance

Sorry No Data Available

Share Price Chart (5 years)

Mereo Biopharma Historic Returns

Sorry No Data Available

Mereo Biopharma Key Management Ratios

Mereo Biopharma Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio- 
PE Ratio- 
Tobin's Q Ratio 0.94 
Tobin's Q Ratio (excl. intangibles)1.89 
Dividend Yield-%
Market-to-Book Ratio1.80 
Price-to-Pre-Tax Profit PS-1.76 
Price-to-Retained Profit PS-2.08 
Price-to-Cash Flow PS-1.58 
Price-to-Sales PS- 
Price-to-Net Tangible Asset Value PS-17.27 
Price-to-Cash PS4.44 
Net Working Capital PS0.20 
Price Pct to Working Capital PS130.19%
Earnings Yield-%
Average PE- 
Years in average- 
PE to PE average-%

Mereo Biopharma Financial Ratios

(Leverage Ratios)
Debt Ratio28.84%
Debt-to-Equity Ratio0.41 
Debt-to-Equity Ratio (excl. Intgbl)-3.88 
Debt-to-Equity Market Value0.22 
Net Gearing34.52%
Net Gearing (excl. Intangibles)71.07%
Gross Gearing53.43%
Gross Gearing (excl. Intangibles)110.00%
Gearing Under 1 Year34.56%
Gearing Under 1 Year (excl. Intgbl)71.15%
(Liquidity Ratios)
Net Working Capital to Total Assets0.64%
Current Ratio1.02 
Quick Ratio (Acid Test)1.02 
Liquidity Ratio0.55 
Cash & Equiv/Current Assets53.71%
(Solvency Ratios)
Enterprise Value72.49m
CFO/Attributable Profit- 
Total Debt/Equity Market Value0.64 
Total Debt/Sales- 
Total Debt/Pre-Tax Profit-1.12 
Total Debt46.19m
Total Debt/Net Current Assets82.93%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-11.36%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs- 
Beta (60-Mnth)Beta (36-Mnth)

Mereo Biopharma Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)-72.68%
Return On Assets (ROA)-45.33%
Net Profit Margin-%
Assets Turnover- 
Return On Equity (ROE)-86.56%
Return On Investment (ROI)-64.72%
Dividend Payout Ratio-%
Plowback Ratio100.00%
Growth from Plowback Ratio-%
Net Income Of Revenues-%
(Asset Utilisation Multiples)
Shareholders Equity Turnover- 
Fixed Assets Turnover- 
Current Assets Turnover- 
Net Working Capital Turnover 
Inventory Turnover- 
(Other Operating Ratios)
Total Assets-to-Sales- 
Debt Collection Period-Days

Mereo Biopharma Dividends

Sorry No Data Available

Mereo Biopharma Fundamentals

 31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)
pre tax profit-33.72--46.95--37.31--41.12-m
attributable profit-28.39--38.80--32.03--34.84-m
retained profit-28.39--38.80--32.03--34.84-m
eps - basic (p)-63.00 -56.00 -45.00 -39.00 
eps - diluted (p)-63.00 -56.00 -45.00 -39.00 
dividends per share- - - - 

Mereo Biopharma Balance Sheet

 31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)
 31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)
fixed assets fixed assets0.170.20%0.150.16%0.150.22%11.5613.37%m
intangibles intangibles25.8129.75%33.0134.26%32.6348.50%44.4651.42%m
fixed investments fixed investments--%2.502.60%2.503.72%--%m
current assets - other current assets - other--%--%--%--%m
stocks stocks--%--%--%--%m
debtors debtors7.208.30%10.6311.04%6.9510.34%14.0916.30%m
cash & securities cash & securities53.5861.75%50.0451.95%25.0437.22%16.3518.91%m
creditors - short creditors - short3.213.70%9.629.98%16.1824.05%29.8834.56%m
creditors - long creditors - long4.304.95%24.2325.16%18.3327.24%16.3218.87%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
ord cap, reserves ord cap, reserves79.2691.35%62.4864.86%32.7748.71%40.2646.57%m
prefs, minorities prefs, minorities--%--%--%--%m
NAV Basic- - - - 
NAV Diluted- - - - 

Mereo Biopharma Cash Flow Statement

31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)
Operating CF-27.40-32.15-23.14-45.93m
Pre-Financing CF-27.03-35.89-22.89-2.64m
Retained CF41.33-2.15-24.96-8.35m

Mereo Biopharma Brokers

Evolution Securities LimitedMarket Maker(MMF)Broker/DealerEVOEVBGGB21MMT
Shore Capital Stockbrokers LtdMarket Maker(MMF)Broker/DealerSCAPSHOCGB21
Merrill Lynch InternationalMarket Maker(MMF)Broker/DealerMLSBSNCSGB2LBIC
Winterflood Securities LtdMarket Maker(MMF)Broker/DealerWINSWNTSGB2LBIC
ADVFN Advertorial
Your Recent History
Mereo Biop..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20211207 06:22:15